RBC Bioscience

RBC Bioscience Short-term Debt

The Short-Term Debt of RBC Bioscience (6848.TWO) as of Nov 6, 2026 is 77.82 M TWD. In the previous year, Short-Term Debt was 59.05 M TWD — a change of 31.79% (higher).

Short-term Debt

77.82 MTWD

YoY

31.79%

Last updated:

Short-Term Debt of RBC Bioscience is 2024 77.82 M TWD. Short-Term Debt of RBC Bioscience was 2023 59.05 M TWD. It decreases by 31.79% higher compared to the previous year.

The RBC Bioscience Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
8.10 M TWD
Jan 1, 2019
48.31 M TWD
Jan 1, 2020
78.89 M TWD
Jan 1, 2021
68.74 M TWD
Jan 1, 2022
64.46 M TWD
Jan 1, 2023
59.05 M TWD
Jan 1, 2024
77.82 M TWD
The RBC Bioscience Short-term Debt history
YEARShort-term DebtYoY
77.82 MTWD+31.79%
59.05 MTWD-8.40%
64.46 MTWD-6.22%
68.74 MTWD-12.87%
78.89 MTWD+63.31%
48.31 MTWD+496.36%
8.10 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Short-Term Debt of RBC Bioscience is 77.82 M TWD in 2024.

Short-Term Debt of RBC Bioscience changed from 59.05 M TWD to 77.82 M TWD, representing a 31.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's RBC Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RBC Bioscience

All Key Metrics — RBC Bioscience